BR112021002953A2 - polipeptídeos anti-her2 e métodos de uso dos mesmos - Google Patents
polipeptídeos anti-her2 e métodos de uso dos mesmos Download PDFInfo
- Publication number
- BR112021002953A2 BR112021002953A2 BR112021002953-2A BR112021002953A BR112021002953A2 BR 112021002953 A2 BR112021002953 A2 BR 112021002953A2 BR 112021002953 A BR112021002953 A BR 112021002953A BR 112021002953 A2 BR112021002953 A2 BR 112021002953A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- seq
- variable region
- acid sequence
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721505P | 2018-08-22 | 2018-08-22 | |
| US62/721,505 | 2018-08-22 | ||
| PCT/US2019/047728 WO2020041604A1 (en) | 2018-08-22 | 2019-08-22 | Anti-her2 polypeptides and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021002953A2 true BR112021002953A2 (pt) | 2021-05-11 |
Family
ID=67989062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021002953-2A BR112021002953A2 (pt) | 2018-08-22 | 2019-08-22 | polipeptídeos anti-her2 e métodos de uso dos mesmos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220002436A1 (https=) |
| EP (1) | EP3840781A1 (https=) |
| JP (2) | JP2021534220A (https=) |
| KR (1) | KR20210074279A (https=) |
| CN (1) | CN113286610A (https=) |
| AR (1) | AR115998A1 (https=) |
| AU (2) | AU2019326545A1 (https=) |
| BR (1) | BR112021002953A2 (https=) |
| CA (1) | CA3141815A1 (https=) |
| EA (1) | EA202190603A1 (https=) |
| IL (2) | IL326298A (https=) |
| MX (1) | MX2021001976A (https=) |
| SG (1) | SG11202101436SA (https=) |
| TW (1) | TW202017947A (https=) |
| WO (1) | WO2020041604A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| PH12022551598A1 (en) | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| AU2021224200A1 (en) * | 2020-02-19 | 2022-09-08 | Denali Therapeutics Inc. | Engineered anti-HER2 bispecific proteins |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| WO2023038803A2 (en) * | 2021-08-25 | 2023-03-16 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| WO2023128702A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
| KR20240067001A (ko) * | 2022-10-28 | 2024-05-16 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
| EP4631975A1 (en) * | 2022-12-08 | 2025-10-15 | Adel Inc. | Fusion comprising anti-tau antibody and peptide and use thereof |
| CN120648654A (zh) * | 2024-03-13 | 2025-09-16 | 深圳太力生物技术有限责任公司 | 重组细胞的制备方法、重组细胞及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1699826B1 (en) * | 2005-01-05 | 2009-03-11 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| HUE045144T2 (hu) * | 2012-08-29 | 2019-12-30 | Hoffmann La Roche | Véragygát-shuttle |
| WO2014089209A2 (en) * | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| WO2015191934A2 (en) * | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
| CN107531788B (zh) * | 2015-06-24 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 对her2和血脑屏障受体特异性的三特异性抗体及使用方法 |
| CN107446045A (zh) * | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | 一种抗her2的抗体、其药物组合物及用途 |
| CN110506055A (zh) * | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| SG11201907422RA (en) * | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| EP3665194A4 (en) * | 2017-08-10 | 2021-07-07 | Denali Therapeutics Inc. | AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS |
-
2019
- 2019-08-22 JP JP2021510094A patent/JP2021534220A/ja active Pending
- 2019-08-22 CN CN201980068845.5A patent/CN113286610A/zh active Pending
- 2019-08-22 WO PCT/US2019/047728 patent/WO2020041604A1/en not_active Ceased
- 2019-08-22 IL IL326298A patent/IL326298A/en unknown
- 2019-08-22 MX MX2021001976A patent/MX2021001976A/es unknown
- 2019-08-22 SG SG11202101436SA patent/SG11202101436SA/en unknown
- 2019-08-22 EA EA202190603A patent/EA202190603A1/ru unknown
- 2019-08-22 TW TW108130121A patent/TW202017947A/zh unknown
- 2019-08-22 AU AU2019326545A patent/AU2019326545A1/en not_active Abandoned
- 2019-08-22 EP EP19769934.1A patent/EP3840781A1/en active Pending
- 2019-08-22 BR BR112021002953-2A patent/BR112021002953A2/pt unknown
- 2019-08-22 AR ARP190102390A patent/AR115998A1/es unknown
- 2019-08-22 CA CA3141815A patent/CA3141815A1/en active Pending
- 2019-08-22 KR KR1020217008163A patent/KR20210074279A/ko not_active Ceased
-
2021
- 2021-02-16 IL IL280922A patent/IL280922B1/en unknown
- 2021-02-18 US US17/178,595 patent/US20220002436A1/en active Pending
-
2024
- 2024-07-25 JP JP2024119250A patent/JP7818042B2/ja active Active
-
2026
- 2026-01-07 AU AU2026200081A patent/AU2026200081A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113286610A (zh) | 2021-08-20 |
| IL280922B1 (en) | 2026-03-01 |
| AR115998A1 (es) | 2021-03-25 |
| WO2020041604A1 (en) | 2020-02-27 |
| US20220002436A1 (en) | 2022-01-06 |
| JP2024150674A (ja) | 2024-10-23 |
| IL280922A (en) | 2021-04-29 |
| EA202190603A1 (ru) | 2021-07-14 |
| CA3141815A1 (en) | 2020-02-27 |
| EP3840781A1 (en) | 2021-06-30 |
| KR20210074279A (ko) | 2021-06-21 |
| AU2026200081A1 (en) | 2026-01-29 |
| JP7818042B2 (ja) | 2026-02-19 |
| MX2021001976A (es) | 2021-06-08 |
| AU2019326545A1 (en) | 2021-03-11 |
| SG11202101436SA (en) | 2021-03-30 |
| TW202017947A (zh) | 2020-05-16 |
| IL326298A (en) | 2026-04-01 |
| JP2021534220A (ja) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7818042B2 (ja) | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 | |
| JP7397063B2 (ja) | 操作された二重特異性タンパク質 | |
| BR112020013921A2 (pt) | polipeptídeos de ligação ao receptor de transferrina e usos destes | |
| CN105658235A (zh) | 能够结合gpA33和CD3的双特异性单价双抗体及其用途 | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| WO2022242679A1 (en) | Anti-cd137 antibodies and methods of use | |
| US20240190989A1 (en) | Anti-cea and anti-cd137 multispecific antibodies and methods of use | |
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins | |
| US20240209113A1 (en) | Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use | |
| KR20240052019A (ko) | 항-her2 항체 및 이의 사용 방법 | |
| TW202430568A (zh) | 抗b7h3抗體以及其使用方法 | |
| CN120603850A (zh) | 抗cmet抗体及使用方法 | |
| HK40084724A (en) | Engineered anti-her2 bispecific proteins | |
| HK40107933A (zh) | 抗gpc3和抗cd137多特异性抗体及使用方法 | |
| HK40110414A (zh) | 抗her2抗体及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |